Impact of postoperative omega-3 fatty acid-supplemented parenteral nutrition on clinical outcomes and immunomodulations in colorectal cancer patients

Table 1 Demographic characteristics of the patients at entry (mean ± SD)

Group	Group FO	Group SO	t or χ2	P
	(n = 20)	(n = 21)
Age (yr)	55.80 ± 10.10	59.19 ± 10.61	1.047	0.3
Weight (kg)	63.50 ± 8.86	65.40 ± 9.20	0.675	0.5
Height (cm)	164.55 ± 6.68	165.29 ± 7.60	0.329	0.74
BMI	23.38 ± 2.38	23.92 ± 2.84	0.655	0.52
Gender (male/female)	10/10	15/6	1.977	0.16
Diagnosis
(colon cancer/rectal cancer)	11/9	12/9	0.019	0.89
TNM stage
Stage I	0	3	3.2	0.21
Stage II	10	10
Stage III	10	8

Table 2 Regimen of daily TPN in the FO and SO groups/kg body weight (g)

Day	Both groups		SO + FO lipids	SO lipids
	Glucose	Nitrogen
POD+1	3.0	0.18	0.5 SO + 0.1 FO	0.6 SO
POD+2-POD+7	3.0	0.18	1.0 SO + 0.2 FO	1.2 SO

Table 3 Counts of white blood cells, platelets, and γ-glutamyltranspeptidase before and after operation in the FO group versus the SO group (mean ± SD)

Group	n	WBC (× 109)				Plt (× 109)				r-GT (U/L)
		POD-1	POD+1	POD+8	1	POD-1	POD+1	POD+8	1	POD-1	POD+1	POD+8	1
FO	20	6.76 ± 2.01	11.20 ± 2.31	8.17 ± 1.37	-3.03 ± 2.46	241.93 ± 56.62	181.50 ± 73.47	262.72 ± 58.63	81.22 ± 61.58	23.30 ± 11.55	14.30 ± 9.26	37.20 ± 24.49	22.90 ± 21.35
SO	21	7.03 ± 2.59	11.70 ± 3.32	9.03 ± 2.58	-2.67 ± 2.58	221.51 ± 44.20	176.51 ± 41.25	264.60 ± 74.13	88.08 ± 67.07	17.43 ± 5.80	12.76 ± 7.89	48.48 ± 28.41	35.71 ± 25.34
t		0.381	0.567	1.322	0.447	1.290	0.270	0.090	0.341	2.072	0.574	1.358	1.747
P		0.71	0.57	0.19	0.66	0.20	0.79	0.93	0.74	0.05	0.57	0.18	0.09

1: The margin value for POD+8 minus POD+1.

Table 4 Assessment of inflammatory and immunological parameters before and after operation in the FO group versus the SO group (mean ± SD)

Group	n	IL-6 (pg/mL)					TNF-α(pg/mL)
		POD-1	POD+1	POD+8	1	2	POD-1	POD+1	POD+8	1	2
FO	20	9.02 ± 23.25	59.66 ± 31.91	15.23 ± 8.42	50.64 ± 32.21	-44.43 ± 30.53	2.74 ± 2.00	3.31 ± 2.85	2.49 ± 2.06	0.57 ± 3.46	-0.82 ± 2.71
SO	21	10.42 ± 10.75	42.60 ± 50.12	34.21 ± 44.12	32.18 ± 47.69	-8.39 ± 69.08	2.48 ± 3.73	2.66 ± 2.76	2.94 ± 3.12	0.18 ± 4.50	0.27 ± 1.67
t		0.249	1.292	1.935	1.445	2.141	0.270	0.738	0.544	0.312	1.570
P		0.804	0.204	0.066	0.156	0.039	0.789	0.465	0.590	0.757	0.125

Table 5 Assessment of inflammatory and immunological parameters before and after operation in the FO group versus the SO group (mean ± SD)

Group	n	CD8+(%)					Ratio of CD4+/CD8+
		POD-1	POD+1	POD+8	1	2	POD-1	POD+1	POD+8	1	2
FO	20	25.89 ± 8.09	28.87 ± 7.63	25.46 ± 7.20	2.99 ± 7.20	-3.41 ± 5.79	1.54 ± 0.79	0.89 ± 0.52	1.80 ± 0.74	-0.65 ± 0.69	0.92 ± 0.62
SO	21	26.12 ± 10.95	26.50 ± 12.08	26.31 ± 9.85	0.38 ± 13.07	-0.19 ± 10.12	1.32 ± 0.50	1.27 ± 1.34	1.52 ± 0.69	-0.05 ± 1.28	0.25 ± 1.22
t		0.079	0.747	0.316	0.786	1.244	1.067	1.195	1.269	1.854	2.186
P		0.937	0.460	0.754	0.437	0.221	0.293	0.239	0.212	0.071	0.035

Table 6 Assessment of inflammatory and immunological parameters before and after operation in the FO group versus the SO group (mean ± SD)

Group	n	CD3+ (%)					CD4+ (%)
		POD-1	POD+1	POD+8	1	2	POD-1	POD+1	POD+8	1	2
FO	20	65.81 ± 9.52	56.43 ± 12.57	69.28 ± 9.42	-9.38 ± 9.88	12.85 ± 11.61	35.69 ± 11.48	23.68 ± 10.69	41.48 ± 9.51	-12.02 ± 10.79	17.80 ± 10.86
SO	21	57.41 ± 11.11	59.73 ± 16.06	63.57 ± 10.26	2.32 ± 20.36	3.84 ± 19.62	30.46 ± 9.74	24.41 ± 15.87	34.07 ± 10.17	-6.05 ± 17.95	9.66 ± 17.55
t		2.591	0.731	1.851	2.320	1.799	1.575	0.173	2.405	1.281	1.775
P		0.013	0.469	0.072	0.026	0.081	0.123	0.864	0.021	0.208	0.084

1: The margin value for POD+1 minus POD-1; 2: The margin value for POD+8 minus POD+1.